Search

Your search keyword '"Bray, Amy"' showing total 14 results
Start Over Author "Bray, Amy"
14 results on '"Bray, Amy"'

1. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

Author

Gebrehana, Beza, Greenleaf, Melissa E, Hamer, Melinda J, Jansen, Nathan K, Jing, Xiaotang, Kagai, Jael, Kourbanova, Kamila, Koren, Michael A, Martin, Monica L, Wuertz, Kathryn McGuckin, Regules, Jason A, Sanborn, Aaron D, Wallace, David, Zhu, Lei, Gromowski, Gregory D, Corbitt, Courtney, Darden, Janice M, Dussupt, Vincent, Golub, Emily S, Headley, Jarrett A, Jarral, Umair M, King, Jocelyn, Krebs, Shelly J, Lay, Jenny, Lilly, Regina, Lynch, Jennifer, Martinez, Elizabeth J, Mayer, Sandra V, McGeehon, Samantha, Lee, Hyunna, Schech, Steven, Tadesse, Mekdi, Thomas, Paul V, Romem, Yahel, Zografos, Erifile, Lin, Bob C, Narpala, Sandeep R, Wang, Lingshu, Doria-Rose, Nicole A, Carroll, Robin E, Eaton, Amanda, Badraslioglu, Emily D, Koontz, Jason M, Nwaeze, Ugo E, Dawson, Peter, Noll, Alexander J, Orndahl, Christine M, Bray, Amy, Carrion, Ricardo, Jr., Patterson, Jean, Kulkarni, Viraj, Hallam, Cory, Gonzalez, Olga, Gazi, Michal, Ober Shepherd, Brittany L, Scott, Paul T, Hutter, Jack N, Lee, Christine, McCauley, Melanie D, Guzman, Ivelese, Bryant, Christopher, McGuire, Sarah, Kennedy, Jessie, Chen, Wei-Hung, Hajduczki, Agnes, Mdluli, Thembi, Valencia-Ruiz, Anais, Amare, Mihret F, Matyas, Gary R, Rao, Mangala, Rolland, Morgane, Mascola, John R, De Rosa, Stephen C, McElrath, M Juliana, Montefiori, David C, Serebryannyy, Leonid, McDermott, Adrian B, Peel, Sheila A, Collins, Natalie D, Joyce, M Gordon, Robb, Merlin L, Michael, Nelson L, Vasan, Sandhya, and Modjarrad, Kayvon

Published
2024
Full Text
View/download PDF

2. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

Author

Ober Shepherd, Brittany L, primary, Scott, Paul T, additional, Hutter, Jack N, additional, Lee, Christine, additional, McCauley, Melanie D, additional, Guzman, Ivelese, additional, Bryant, Christopher, additional, McGuire, Sarah, additional, Kennedy, Jessie, additional, Chen, Wei-Hung, additional, Hajduczki, Agnes, additional, Mdluli, Thembi, additional, Valencia-Ruiz, Anais, additional, Amare, Mihret F, additional, Matyas, Gary R, additional, Rao, Mangala, additional, Rolland, Morgane, additional, Mascola, John R, additional, De Rosa, Stephen C, additional, McElrath, M Juliana, additional, Montefiori, David C, additional, Serebryannyy, Leonid, additional, McDermott, Adrian B, additional, Peel, Sheila A, additional, Collins, Natalie D, additional, Joyce, M Gordon, additional, Robb, Merlin L, additional, Michael, Nelson L, additional, Vasan, Sandhya, additional, Modjarrad, Kayvon, additional, Gebrehana, Beza, additional, Greenleaf, Melissa E, additional, Hamer, Melinda J, additional, Jansen, Nathan K, additional, Jing, Xiaotang, additional, Kagai, Jael, additional, Kourbanova, Kamila, additional, Koren, Michael A, additional, Martin, Monica L, additional, Wuertz, Kathryn McGuckin, additional, Regules, Jason A, additional, Sanborn, Aaron D, additional, Wallace, David, additional, Zhu, Lei, additional, Gromowski, Gregory D, additional, Corbitt, Courtney, additional, Darden, Janice M, additional, Dussupt, Vincent, additional, Golub, Emily S, additional, Headley, Jarrett A, additional, Jarral, Umair M, additional, King, Jocelyn, additional, Krebs, Shelly J, additional, Lay, Jenny, additional, Lilly, Regina, additional, Lynch, Jennifer, additional, Martinez, Elizabeth J, additional, Mayer, Sandra V, additional, McGeehon, Samantha, additional, Lee, Hyunna, additional, Schech, Steven, additional, Tadesse, Mekdi, additional, Thomas, Paul V, additional, Romem, Yahel, additional, Zografos, Erifile, additional, Lin, Bob C, additional, Narpala, Sandeep R, additional, Wang, Lingshu, additional, Doria-Rose, Nicole A, additional, Carroll, Robin E, additional, Eaton, Amanda, additional, Badraslioglu, Emily D, additional, Koontz, Jason M, additional, Nwaeze, Ugo E, additional, Dawson, Peter, additional, Noll, Alexander J, additional, Orndahl, Christine M, additional, Bray, Amy, additional, Carrion, Ricardo, additional, Patterson, Jean, additional, Kulkarni, Viraj, additional, Hallam, Cory, additional, Gonzalez, Olga, additional, and Gazi, Michal, additional

Published
2024
Full Text
View/download PDF

3. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

Author

Butler, Ellie, Winter, Jean, Xu, Jianguo, Sherman, Amy, Kelley, Colleen, Fredrick, Rameses, Rouphael, Nadine, Phadke, Varun, Whitney, Cynthia, Alvarez, Alicarmen, Dennis, Renata, Fineman, Rebecca, Lankford-Turner, Pamela, Yi, Sha, Lai, Lilin, Burch, Gena, Gupta, Shanker, Berkowitz, Nina, Carter, Cristina, Beck, Allison, Larkin, Brenda, Taylor, Stephanie, Alger, Mandy, Bahorich, Jessica, Lynch Chamberlain, Amy, Chang, Ya-chen, Chaudhuri, Rajoshi, Cooper, Jonathan, Demirji, Jacob, Yang, Fan, Fernald, Alissa, Gollapudi, Deepika, Holland-Linn, Janel, Kueltzo, Lisa, Lee, James, Liu, Jie, Liu, Xun, Mowery, Rachel, O'Connell, Sarah, Rosales-Zavala, Erwin, Sands, Jason, Wang, Xin, Weng, Shaojie, Witter, Sara, Coates, Emily E, Edupuganti, Srilatha, Chen, Grace L, Happe, Myra, Strom, Larisa, Widge, Alicia, Florez, Maria Burgos, Cox, Josephine H, Gordon, Ingelise, Plummer, Sarah, Ola, Abidemi, Yamshchikov, Galina, Andrews, Charla, Curate-Ingram, Sharon, Morgan, Patricia, Nagar, Shashi, Collins, Matthew H, Bray, Amy, Nguyen, Thuy, Stein, Judy, Case, Christopher L, Kaltovich, Florence, Wycuff, Diane, Liang, C Jason, Carlton, Kevin, Vazquez, Sandra, Mascola, John R, and Ledgerwood, Julie E

Published
2022
Full Text
View/download PDF

5. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

Author

Coates, Emily E, primary, Edupuganti, Srilatha, additional, Chen, Grace L, additional, Happe, Myra, additional, Strom, Larisa, additional, Widge, Alicia, additional, Florez, Maria Burgos, additional, Cox, Josephine H, additional, Gordon, Ingelise, additional, Plummer, Sarah, additional, Ola, Abidemi, additional, Yamshchikov, Galina, additional, Andrews, Charla, additional, Curate-Ingram, Sharon, additional, Morgan, Patricia, additional, Nagar, Shashi, additional, Collins, Matthew H, additional, Bray, Amy, additional, Nguyen, Thuy, additional, Stein, Judy, additional, Case, Christopher L, additional, Kaltovich, Florence, additional, Wycuff, Diane, additional, Liang, C Jason, additional, Carlton, Kevin, additional, Vazquez, Sandra, additional, Mascola, John R, additional, Ledgerwood, Julie E, additional, Butler, Ellie, additional, Winter, Jean, additional, Xu, Jianguo, additional, Sherman, Amy, additional, Kelley, Colleen, additional, Fredrick, Rameses, additional, Rouphael, Nadine, additional, Phadke, Varun, additional, Whitney, Cynthia, additional, Alvarez, Alicarmen, additional, Dennis, Renata, additional, Fineman, Rebecca, additional, Lankford-Turner, Pamela, additional, Yi, Sha, additional, Lai, Lilin, additional, Burch, Gena, additional, Gupta, Shanker, additional, Berkowitz, Nina, additional, Carter, Cristina, additional, Beck, Allison, additional, Larkin, Brenda, additional, Taylor, Stephanie, additional, Alger, Mandy, additional, Bahorich, Jessica, additional, Lynch Chamberlain, Amy, additional, Chang, Ya-chen, additional, Chaudhuri, Rajoshi, additional, Cooper, Jonathan, additional, Demirji, Jacob, additional, Yang, Fan, additional, Fernald, Alissa, additional, Gollapudi, Deepika, additional, Holland-Linn, Janel, additional, Kueltzo, Lisa, additional, Lee, James, additional, Liu, Jie, additional, Liu, Xun, additional, Mowery, Rachel, additional, O'Connell, Sarah, additional, Rosales-Zavala, Erwin, additional, Sands, Jason, additional, Wang, Xin, additional, Weng, Shaojie, additional, and Witter, Sara, additional

Published
2022
Full Text
View/download PDF

7. Crowdsourcing Artificial Intelligence in Africa: Findings from a Machine Learning Contest

Author

Naudé, Wim, Bray, Amy, and Lee, Celina

Subjects
O31, O33, O55, Africa, ddc:330, crowdsourcing, data science, artificial intelligence, O36, innovation
Abstract

In this paper, we study the crowdsourcing of innovation in Africa through a data science contest on an intermediated digital platform. We ran a Machine Learning (ML) contest on the continent's largest data science contest platform, Zindi. Contestants were surveyed on their motivations to take part and their perceptions about AI in Africa. In total, 614 contestants submitted 15,832 entries, and 559 responded to the accompanying survey. From the findings, we answered several questions: who take part in these contests and why? Who is most likely to win? What are contestants' entrepreneurial aspirations in deploying AI? What are the obstacles they perceive to the greater diffusion of AI in Africa? We conclude that crowdsourcing of AI via data contest platforms offers a potential mechanism to alleviate some of the constraints in the adoption and diffusion of AI in Africa. Recommendations for further research are made.

Published
2021

9. Ever HOPE-ful: the evolution of the Hope for Homeowners Program.

Author

Bray, Amy

Subjects
Foreclosure -- Laws, regulations and rules, Default (Law) -- Laws, regulations and rules, Housing discrimination -- Laws, regulations and rules, Mortgages -- Laws, regulations and rules, Mortgages, Government regulation
Published
2009

10. How to create a green community.

Author

Bray, Amy

Subjects
Sustainable urban development -- Laws, regulations and rules, Government regulation
Published
2008

11. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.

Author

Chen, Grace L., Coates, Emily E., Plummer, Sarah H., Carter, Cristina A., Berkowitz, Nina, Conan-Cibotti, Michelle, Cox, Josephine H., Beck, Allison, O'Callahan, Mark, Andrews, Charla, Gordon, Ingelise J., Larkin, Brenda, Lampley, Rebecca, Kaltovich, Florence, Gall, Jason, Carlton, Kevin, Mendy, Jason, Haney, Doug, May, Jeanine, and Bray, Amy

Subjects
VIRAL vaccines, CHIKUNGUNYA, IMMUNOGLOBULINS, INTRAMUSCULAR injections, RANDOMIZED controlled trials, BLIND experiment, NEUTRALIZATION tests, STATISTICAL sampling, CHIKUNGUNYA virus
Abstract

Importance: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies.Objective: To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions.Design, Setting, and Participants: This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP). The trial was conducted at 6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico. A total of 400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria. The first study enrollment occurred on November 18, 2015; the final study visit, March 6, 2018.Interventions: Participants were randomized 1:1 to receive 2 intramuscular injections 28 days apart (20 µg, n = 201) or placebo (n = 199) and were followed up for 72 weeks.Main Outcomes and Measures: The primary outcome was the safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcome was immune response by neutralization assay 4 weeks after second vaccination.Results: Of the 400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis. All injections were well tolerated. Of the 16 serious adverse events unrelated to the study drugs, 4 (25%) occurred among 4 patients in the vaccine group and 12 (75%) occurred among 11 patients in the placebo group. Of the 16 mild to moderate unsolicited adverse events that were potentially related to the drug, 12 (75%) occurred among 8 patients in the vaccine group and 4 (25%) occurred among 3 patients in the placebo group. All potentially related adverse events resolved without clinical sequelae. At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination.Conclusions and Relevance: Among healthy adults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demonstrated safety and tolerability. Phase 3 trials are needed to assess clinical efficacy.Trial Registration: ClinicalTrials.gov Identifier: NCT02562482. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

13. Trendy or Just Plain Smart? Greening Active Adult Communities.

Author

Bray, Amy

Subjects
SUSTAINABLE architecture, SUSTAINABLE building design & construction, SENIOR housing, OLDER consumers, AIR quality
Abstract

The article presents information on green building design, with reference to the senior housing market. It is stated that the green concept calls for thoughtfulness in design of living spaces and in the things one uses every day. Maximizing the use of daylight to light rooms, energy and water use efficiencies, and improving indoor air quality, are some of the popular green design concepts.

Published
2009

14. Top Trends in Active Adult Communities for 2009.

Author

Bray, Amy

Subjects
HOUSE buying, MINORITIES, SUSTAINABLE building design & construction, LEADERSHIP in Energy & Environmental Design, ENERGY consumption
Abstract

The article reports that the active adult communities are attracting young buyers in greater number, while the minorities are also becoming a large part of the market share. It states that communities are adopting green building concept, and some of them are getting Leadership in Energy & Environmental Design (LEED) certification. It mentions that with the increase in energy prices, people are trying to find the inclusion of energy-efficient appliances, to protect their budget.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results